Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 75, Issue 6, 2006, Pages 429-434

  Kilian, M ^a   Gregor, J I ^a   Heukamp, I ^a   Hanel, M ^a   Ahlgrimm, M ^a   Schimke, I ^a   Kristiansen, G ^a   Ommer, A ^b   Walz, M K ^b   Jacobi, C A ^a   Wenger, F A ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIS(2 OXOPROPYL)NITROSAMINE; EUDRAGIT; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; POLYUNSATURATED FATTY ACID; RO 28 2653; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MEGADOSE; DRUG SELECTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; LIPID DIET; LIVER METASTASIS; LOW DRUG DOSE; MALE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; SYRIAN HAMSTER;

ANIMALS; CARCINOGENS; CARCINOMA, PANCREATIC DUCTAL; CRICETINAE; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESOCRICETUS; NITROSAMINES; PANCREATIC NEOPLASMS; PIPERAZINES; PROTEASE INHIBITORS; PYRIMIDINES;

CRICETINAE; MESOCRICETUS AURATUS;

EID: 33750458019     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.08.004     Document Type: Article

References (35)

1. Hawes R.H., Xiong Q., Waxman I., et al. A multispeciality approach to the diagnosis and management of pancreatic cancer. Am. J. Gastroenterol. 95 (2000) 17-31
2. Warshaw Al., and Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326 (1992) 455-465
3. Zalatnai. Pancreatic Cancer-a Continuing Challenge in Oncology. Pathol. Oncol. Res. 9 4 (2003) 252-263
4. Alexakis N., Halloran C., Raraty M., Ghaneh P., Sutton R., and Neoptolemos J.P. Current standards of surgery for pancreatic cancer. Br. J. Surg. 91 (2004) 1410-1427
5. Amikura K., and Kobari M. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int. J. Pancreatol. 17 (1995) 139-146
6. Shore S., Raraty M.G.T., Ghaneh P., and Neoptolemos J.P. Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol. Ther. 18 (2003) 1049-1069
7. Neoptolemos J.P., Cunningham D., Friess H., Bassi C., Stocken D.D., et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann. Oncol. 14 (2003) 675-692
8. Gross J., and Lapiere C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. 48 (1962) 1014-1022
9. Maquoi E., Sounni N.E., Devy L., Oliver F., Frankenne F., et al. Anti-invasive, anti-tumoral, and anti-angiogenic efficacy of a Pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinase inhibitor. Clin. Cancer Res. 10 (2004) 4038-4047
10. Qian X., Rothmann V.L., Nicosia R.F., and Tuszynski G.P. Expression of Thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol. Oncol. Res. 7 4 (2001) 251-259
11. Zervos E.E., Shafil A.E., and Rosemurgy A.S. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. J. Surg. Res. 81 (1999) 65-68
12. Koshiba T., Hosotani R., Wada M., Miyamoto Y., Fujimoto K., et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Am. cancer soc. 642-650 (1998)
13. Zervos E.E., Shafil A.E., Haq M., and Rosemurgy A.S. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of Panc-1 cells in vitro. J. Surg. Res. 84 (1999) 162-167
14. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
15. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. 2 (2002) 657-672
16. Yip D., Ahmad A., Karapetis C.S., Hawkins C.A., and Harper P.G. Matrix metalloproteinase inhibitors: applications in oncology 17 (1999) 387-399
17. Wojtowicz-Praga S.M., Dickson R.B., and Hawkins M.J. Matrix metalloproteinase inhibitors. Invest. New Drugs 15 (1997) 61-75
18. Wenger F.A., Jacobi C.A., Kilian M., et al. The impact of laparoscopic biopsy of pancreatic lymph nodes with helium and carbon dioxide on port site and liver metastasis in BOP-induced pancreatic cancer in hamster. Clin. Exp. Metastasis 18 (2000) 11-14
19. Wenger F.A., Jacobi C.A., Kilian M., et al. Does dietary alpha-linoleic acid promote liver metastasis pancreatic carcinoma initiated by BOP in Syrian hamsters?. Ann. Nutr. Metabol. 43 (1999) 121-126
20. Herrington M.K., Permert J., Kazakoff K.R., et al. Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumour initiation in the hamster. Carcinogenesis 14 5 (1993) 1021-1026
21. Birt D.F., Julius A.D., White L.T., and Pour P.M. Enhancement of pancreatic carcinogenesis in hamsters fed a high fat diet ad libitum and at controlled calorie intake. Cancer Res. 49 21 (1989) 5848-5851
22. UKCCCR-Guidelines for the welfare of animals in experimental neoplasia. Cancer Metastasis Rev. 8: (1989); 82-88.
23. New York Academy of Sciences, Ad Hoc committee on animal research. Interdisciplinary principles and guidelines for the use of animals in research, marketing and education.
24. Meijers M., van Garderen-Hoetmer A., Lamers C.B., et al. Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters?. Carcinogenesis 11 (1990) 2223-2226
25. Bloomstom M., Shafii A., Zervos E.E., Rojiani A., and Rosemurgy A.S. MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer. J. Surg. Res. 102 (2002) 35-38
26. Longnecker D.S. Experimental cancer of the pancreas. Curr. Opin. Gastroeterol 7 (1991) 731-738
27. Pour P.M., Runge R.G., Birt D., et al. Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease. Cancer 47 (1981) 1573-1587
28. Zervos E.E., Norman J.G., Gower W.R., Franz M.G., and Rosemurgy A.S. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorgenesis in vivo. J. Surg. Res. 69 (1997) 367-371
29. Matsushita A., Onda M., Uchida E., Maekawa R., and Yoshioka T. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer. Int. J. Cancer 92 (2001) 434-440
30. Jimenenz R., Hartwig W., Antoniu B.A., Compton C.C., Warshaw A.L., et al. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis. Ann. Surg. 231 5 (2000) 644-654
31. Deruygina E., Bourdon M., Reisfeld R., and Strongin A. Remodelling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. 58 (1998) 3743-3750
32. Bramhall S.R., Hallissey M.T., Whiting J., Scholefield J., Tierney G., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer 86 (2002) 1864-1870
33. Zucker S., Cao J., and Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19 (2000) 6642-6650
34. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash DC) 295 (2002) 2387-2392
35. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin. Ther. Targets 7 (2003) 385-397